Grant: Master's Award: Canada Graduate Scholarships
Université de Montréal
$17,500.00
Deciphering the role of TRK-fused gene (TFG) in antiviral innate immunity
EF 2012-13
Résumé
Viruses are cellular parasites that can only replicate within a suitable host cell; they mainly depend on certain cellular mechanisms for their replication. Thereby, interfering with viral replication in a specific manner, i.e. without inflicting damage to the host, with a pharmacological agent becomes problematic. However, a better characterization of innate immunity determinants could transform antiviral treatments by introducing a broad-spectrum therapeutic arsenal to enhance and optimize the normal antiviral response of the host.
The invasion of a host cell by a virus triggers a series of immune responses occurring as a result of an interaction between viral components and surveillance mechanisms of the host. These host-infectious agents interaction usually leads to the production of certain cytokines which eventually disrupt viral replication and dissemination. Interestingly, a protein called TRAF3 has shown to be important in the development of such antiviral response. Although, the precise method by which TRAF3 reacts in such conditions remains elusive. However, the identification by our laboratory of TRK-fused gene (TFG), a protein involved in secretory pathways, as a new partner of TRAF3 could propose new insights about the mechanism underlying the antiviral response.
Thus, the aim of my project is to decipher the role of TFG in the innate antiviral response. The central hypothesis of my project is that TFG is a new TRAF3 partner whose capacity to regulate the secretory pathways allows it to control the antiviral response. Thus, we will characterize the interaction between TFG and TRAF3 and the role of TFG in the innate antiviral immune system. Then, we will establish the link between TFG antiviral influence, its interaction with the secretory pathway as well as with other known members of the antiviral response.
This research program aims to identify and characterize new effectors that could be targeted for future antiviral therapies.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
279563
Name
Marineau Alexandre
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Deciphering the role of TRK-fused gene (TFG) in antiviral innate immunity
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antiviral Assays; Antiviral Response; Antiviral Therapies; Cell Signaling; Innate Immunity; Molecular Biology Techniques; Transcription Factor; Trk-Fused Gene; Type I Interferons Production; Viral Infection
Abstract
Viruses are cellular parasites that can only replicate within a suitable host cell; they mainly depend on certain cellular mechanisms for their replication. Thereby, interfering with viral replication in a specific manner, i.e. without inflicting damage to the host, with a pharmacological agent becomes problematic. However, a better characterization of innate immunity determinants could transform antiviral treatments by introducing a broad-spectrum therapeutic arsenal to enhance and optimize the normal antiviral response of the host.
The invasion of a host cell by a virus triggers a series of immune responses occurring as a result of an interaction between viral components and surveillance mechanisms of the host. These host-infectious agents interaction usually leads to the production of certain cytokines which eventually disrupt viral replication and dissemination. Interestingly, a protein called TRAF3 has shown to be important in the development of such antiviral response. Although, the precise method by which TRAF3 reacts in such conditions remains elusive. However, the identification by our laboratory of TRK-fused gene (TFG), a protein involved in secretory pathways, as a new partner of TRAF3 could propose new insights about the mechanism underlying the antiviral response.
Thus, the aim of my project is to decipher the role of TFG in the innate antiviral response. The central hypothesis of my project is that TFG is a new TRAF3 partner whose capacity to regulate the secretory pathways allows it to control the antiviral response. Thus, we will characterize the interaction between TFG and TRAF3 and the role of TFG in the innate antiviral immune system. Then, we will establish the link between TFG antiviral influence, its interaction with the secretory pathway as well as with other known members of the antiviral response.
This research program aims to identify and characterize new effectors that could be targeted for future antiviral therapies.
Competitiondate
201302
Approvedterm2
1 yr 0 mth
Pinamesdelim
Marineau, Alexandre
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~